Complete report $4,600. DataPack (test volumes, sales forecasts, supplier shares) $2, 900.
This new 282-page report from Venture Planning Group provides analysis of the US respiratory disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.
About this Report
This report presents detailed analysis of the Respiratory Disease market in the US. Current scientific views on epidemiology and etiology are provided for Adenovirus, Influenza, Legionella,Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales forecasts and market segment, including:
- Commercial/Private Labs
- Physician Offices
- Public Health Labs
In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of respiratory disease diagnostic products, by test. Also, the report:
- Examines market applications of Molecular Diagnostics,
Monoclonal Antibodies, Immunoassays, IT and other emerging technologies; thirteen
- Reviews features and operating characteristics of major analyzers used
for respiratory disease testing;
- Profiles key suppliers and potential market entrants developing innovative
technologies and products; and
- Analyzes emerging opportunities, alternative market penetration strategies,
market entry barriers/risks, and strategic planning issues.
The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products in the U.S.
In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as Venture Planning Group’s proprietary data files was conducted.
Contains 282 pages and 23 tables